RCMNY
IMVT icon

Rubric Capital Management (New York)’s Immunovant IMVT Stock Holding History

Rubric Capital Management (New York)’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-569,800
Closed -$21.9M – 64
2023
Q3 		$21.9M Buy
+569,800
New +$12.9M 0.82% 32

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Rubric Capital Management (New York)'s IMVT Position: Q3 2024 in Review

Rubric Capital Management (New York) sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 58,624 shares — an estimated $1.55M sold.

Rubric Capital Management (New York) first reported a position in IMVT in Q2 2024 and held it in 1 quarter. The position peaked at $1.55M in Q2 2024. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Rubric Capital Management (New York) reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 58,624 Immunovant shares in Q3 2024, an estimated $1.55M.
  • Rubric Capital Management (New York) first reported a position in Immunovant in Q2 2024 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Immunovant position peaked at $1.55M in Q2 2024.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2024, filed 13 Nov 2024.